Breaking News

Regeneron Wins BARDA Contract

To manufacture antibody therapies for the potential prevention and treatment of MERS

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Regeneron Pharmaceuticals, Inc. has entered an agreement with the Biomedical Advanced Research and Development Authority (BARDA) of the U.S. Department of Health and Human Services (HHS) to manufacture and study two antibody therapies for the potential prevention and treatment of Middle East Respiratory Syndrome (MERS) using its VelociGene and VelocImmune technologies. HHS will provide as much as $8.9 million of funding to support fill and finish of the antibodies for human use, the preparati...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters